|
1
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Graves A, Hessamodini H, Wong G and Lim
WH: Metastatic renal cell carcinoma: Update on epidemiology,
genetics, and therapeutic modalities. Immunotargets Ther. 2:73–90.
2013.PubMed/NCBI
|
|
3
|
Rodriguez-Vida A, Hutson TE, Bellmunt J
and Strijbos MH: New treatment options for metastatic renal cell
carcinoma. ESMO Open. 2:e0001852017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mattei J, da Silva RD, Sehrt D, Molina WR
and Kim FJ: Targeted therapy in metastatic renal carcinoma. Cancer
Lett. 343:156–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
da Silva RD, Gustafson D, Nogueira L,
Werahera PN, Molina WR and Kim FJ: Targeted therapy for metastatic
renal carcinoma: An update. J Kidney Cancer VHL. 1:63–73. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Posadas EM, Limvorasak S and Figlin RA:
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol.
13:496–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y, Huang Q, Zhou H, Wang Y, Hu X and
Li T: Inhibition of canonical WNT/β-catenin signaling is involved
in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma
cells. Oncotarget. 7:50401–50416. 2016.PubMed/NCBI
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee WD, Wang KC, Tsai YF, Chou PC, Tsai LK
and Chien CL: Subarachnoid hemorrhage promotes proliferation,
differentiation, and migration of neural stem cells via BDNF
upregulation. PLoS One. 11:e01654602016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oliveira SL, Trujillo CA, Negraes PD and
Ulrich H: Effects of ATP and NGF on proliferation and migration of
neural precursor cells. Neurochem Res. 40:1849–1857. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Truzzi F, Marconi A, Lotti R, Dallaglio K,
French LE, Hempstead BL and Pincelli C: Neurotrophins and their
receptors stimulate melanoma cell proliferation and migration. J
Invest Dermatol. 128:2031–2040. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang W, Chen J and Guo X: The role of
nerve growth factor and its receptors in tumorigenesis and cancer
pain. Biosci Trends. 8:68–74. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okugawa Y, Tanaka K, Inoue Y, Kawamura M,
Kawamoto A, Hiro J, Saigusa S, Toiyama Y, Ohi M, Uchida K, et al:
Brain-derived neurotrophic factor/tropomyosin-related kinase B
pathway in gastric cancer. Br J Cancer. 108:121–130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tanaka K, Okugawa Y, Toiyama Y, Inoue Y,
Saigusa S, Kawamura M, Araki T, Uchida K, Mohri Y and Kusunoki M:
Brain-derived neurotrophic factor (BDNF)-induced
tropomyosin-related kinase B (Trk B) signaling is a potential
therapeutic target for peritoneal carcinomatosis arising from
colorectal cancer. PLoS One. 9:e964102014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Faulkner S, Jobling P, Rowe CW, Rodrigues
Oliveira SM, Roselli S, Thorne RF, Oldmeadow C, Attia J, Jiang CC,
Zhang XD, et al: Neurotrophin receptors TrkA, p75NTR,
and sortilin are increased and targetable in thyroid cancer. Am J
Pathol. 188:229–241. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De la Cruz-Morcillo MA, Berger J,
Sánchez-Prieto R, Saada S, Naves T, Guillaudeau A, Perraud A,
Sindou P, Lacroix A, Descazeaud A, et al: p75 neurotrophin receptor
and pro-BDNF promote cell survival and migration in clear cell
renal cell carcinoma. Oncotarget. 7:34480–34497. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lagadec C, Meignan S, Adriaenssens E,
Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H
and Le Bourhis X: TrkA overexpression enhances growth and
metastasis of breast cancer cells. Oncogene. 28:1960–1970. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vera C, Tapia V, Vega M and Romero C: Role
of nerve growth factor and its TRKA receptor in normal ovarian and
epithelial ovarian cancer angiogenesis. J Ovarian Res. 7:822014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Griffin N, Faulkner S, Jobling P and
Hondermarck H: Targeting neurotrophin signaling in cancer: The
renaissance. Pharmacol Res. 135:12–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Demir IE, Tieftrunk E, Schorn S, Friess H
and Ceyhan GO: Nerve growth factor & TrkA as novel therapeutic
targets in cancer. Biochim Biophys Acta. 1866:37–50.
2016.PubMed/NCBI
|
|
21
|
Yu X, Liu Z, Hou R, Nie Y and Chen R:
Nerve growth factor and its receptors on onset and diagnosis of
ovarian cancer. Oncol Lett. 14:2864–2868. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tomellini E, Touil Y, Lagadec C, Julien S,
Ostyn P, Ziental-Gelus N, Meignan S, Lengrand J, Adriaenssens E,
Polakowska R and Le Bourhis X: Nerve growth factor and proNGF
simultaneously promote symmetric self-renewal, quiescence, and
epithelial to mesenchymal transition to enlarge the breast cancer
stem cell compartment. Stem Cells. 33:342–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liss MA, Gordon A, Morales B, Osann K,
Skarecky D, Lusch A, Zaldivar F and Ahlering TE: Urinary nerve
growth factor as an oncologic biomarker for prostate cancer
aggressiveness. Urol Oncol. 32:714–719. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ghatalia P, Yang ES, Lasseigne BN, Ramaker
RC, Cooper SJ, Chen D, Sudarshan S, Wei S, Guru AS, Zhao A, et al:
Kinase gene expression profiling of metastatic clear cell renal
cell carcinoma tissue identifies potential new therapeutic targets.
PLoS One. 11:e01609242016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang P, Xing Z, Li X, Song Y, Zhao J,
Xiao Y and Xing Y: Tyrosine receptor kinase B silencing inhibits
anoikis-resistance and improves anticancer efficiency of sorafenib
in human renal cancer cells. Int J Oncol. 48:1417–1425. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fang Z, Han B, Jung KH, Lee JH, El-Damasy
AK, Gadhe CG, Kim SJ, Yan HH, Park JH, Lee JE, et al: A novel
tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic
cancer. Cancer Lett. 426:25–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Albaugh P, Fan Y, Mi Y, Sun F, Adrian F,
Li N, Jia Y, Sarkisova Y, Kreusch A, Hood T, et al: Discovery of
GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer
tumor models. ACS Med Chem Lett. 3:140–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Z, Zhang Y, Tong Y, Tong J and Thiele
CJ: Trk inhibitor attenuates the BDNF/TrkB-induced protection of
neuroblastoma cells from etoposide in vitro and in vivo. Cancer
Biol Ther. 16:477–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Croucher JL, Iyer R, Li N, Molteni V,
Loren J, Gordon WP, Tuntland T, Liu B and Brodeur GM: TrkB
inhibition by GNF-4256 slows growth and enhances chemotherapeutic
efficacy in neuroblastoma xenografts. Cancer Chemother Pharmacol.
75:131–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bapat AA, Munoz RM, Von Hoff DD and Han H:
Blocking nerve growth factor signaling reduces the neural invasion
potential of pancreatic cancer cells. PLoS One. 11:e01655862016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kupferman ME, Jiffar T, El-Naggar A,
Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D and
Myers JN: TrkB induces EMT and has a key role in invasion of head
and neck squamous cell carcinoma. Oncogene. 29:2047–2059. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hedrick NG, Harward SC, Hall CE, Murakoshi
H, McNamara JO and Yasuda R: Rho GTPase complementation underlies
BDNF-dependent homo- and heterosynaptic plasticity. Nature.
538:104–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adriaenssens E, Vanhecke E, Saule P,
Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X and Hondermarck
H: Nerve growth factor is a potential therapeutic target in breast
cancer. Cancer Res. 68:346–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang J, Wang LS, Ye SL, Luo P and Wang
BL: Blockage of tropomyosin receptor kinase a (TrkA) enhances
chemo-sensitivity in breast cancer cells and inhibits metastasis in
vivo. Int J Clin Exp Med. 8:634–641. 2015.PubMed/NCBI
|
|
35
|
Sinkevicius KW, Kriegel C, Bellaria KJ,
Lee J, Lau AN, Leeman KT, Zhou P, Beede AM, Fillmore CM, Caswell D,
et al: Neurotrophin receptor TrkB promotes lung adenocarcinoma
metastasis. Proc Natl Acad Sci USA. 111:10299–10304. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Diaz-Montero CM, Mao FJ, Barnard J, Parker
Y, Zamanian-Daryoush M, Pink JJ, Finke JH, Rini BI and Lindner DJ:
MEK inhibition abrogates sunitinib resistance in a renal cell
carcinoma patient-derived xenograft model. Br J Cancer.
115:920–928. 2016. View Article : Google Scholar : PubMed/NCBI
|
